| 货号 | HC359326 |
|---|
| 品牌 | abinScience |
|---|
| 种属反应性 | Human |
|---|
| 应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| 宿主 | Human |
|---|
| 同种型 | IgG |
|---|
| 克隆号 | ZL-1201 |
|---|
| 生物活性 | ZL-1201 (15 min) binds to CD47 on Jurkat cells [1]. ZL-1201 (10 ug/mL; 30 min) when combined with Trastuzumab (), Cetuximab (), or Rituximab () significantly increases phagocytosis index compared to single agents or isotype control [1]. ZL-1201 (2 h) does not induce hemagglutination in whole blood [1]. ZL-1201 (10 mg/kg; i.p.; twice per week; 3–12 weeks) enhances antitumor efficacy in BALB/c nude mice with lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer xenografts (with a TGI of >80% in Raji lymphoma xenografts) [1]. |
|---|
| 表达系统 | Mammalian cells |
|---|
| 克隆类型 | Monoclonal |
|---|
| 靶标 | Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6 |
|---|
| 内毒素水平 | < 10 EU/mg |
|---|
| 纯度 | >95% purity as determined by SDS-PAGE. |
|---|
| 纯化方式 | Protein A/G purified from cell culture supernatant. |
|---|
| Accession号 | Q08722 |
|---|
| 状态 | Liquid |
|---|
| 保存溶液 |
0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
|
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
|---|
| 别名 | ZL-1201, ZL1201, ZL1201 |
|---|
| 背景 | Leukocyte surface antigen CD47 (MER6) is a ~35 kDa protein. Adhesive protein that mediates cell-to-cell interactions. Acts as a receptor for thrombospondin THBS1 and as modulator of integrin signaling through the activation of heterotrimeric G proteins. Involved in signal transduction, cardiovascular homeostasis, inflammation, apoptosis, angiogenesis, cellular self-renewal, and immunoregulation. Plays a role in modulating pulmonary endothelin EDN1 signaling. Modulates nitrous oxide (NO) signaling, in response to THBS1, hence playing a role as a pressor agent, supporting blood pressure. CD47 is the therapeutic target of magrolimab (clinical). 1. Latour, S. et al. (2001) Journal of immunology (Baltimore, Md. : 1950) 167, 2547-54. PMID: 115095943. Isenberg, JS. et al. (2009) The Journal of biological chemistry 284, 1116-25. PMID: 190048354. Lindberg, FP. et al. (1993) The Journal of cell biology 123, 485-96. PMID: 76918315. Gao, AG. et al. (1996) The Journal of biological chemistry 271, 21-4. PMID: 85505626. Rogers, NM. et al. (2017) Cardiovascular research 113, 15-29. PMID: 27742621 |
|---|
| 文献 | 1. Cao A, et al. CD47-blocking Antibody ZL-1201 Promotes Tumor-associated Macrophage Phagocytic Activity and Enhances the Efficacy of the Therapeutic Antibodies and Chemotherapy. Cancer Res Commun. 2022;2(11):1404-1417. Published 2022 Nov 10. [HC359326] |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
